Drug data last refreshed 23h ago · AI intelligence enriched 1mo ago
AMINOSYN 8.5% is an injectable amino acid formulation used for parenteral nutritional support in patients unable to meet protein requirements orally. This established product provides essential and non-essential amino acids intravenously, supporting protein synthesis and metabolic function.
As LOE approaches with moderate competitive pressure (30%), expect gradual team restructuring and focus shift toward cost optimization and retention strategies rather than growth-phase expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Nutritional Status in Patients With Chronic Kidney Disease Receiving 7.2% Amino Acids During Hemodialysis
The Effects of a Dialysis-Specific Formula Rich in Branched-Chain Amino Acids, Omega-3, and Dietary Fiber on Nutritional Status
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
The Glucagonotropic Effect of Amino Acids in Humans
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)
Worked on AMINOSYN 8.5% at ICU Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on AMINOSYN 8.5% offers limited new-product-launch excitement but provides solid experience in mature product management, cost defense, and market share protection in a stable hospital nutrition space. Career development will focus on operational excellence and strategic decision-making around portfolio rationalization rather than growth scaling.